Exposed collagen-targeted fusion cytokine for immune modulation in invasive cancers and lesions of infections

A method of treating an infection in a subject comprising administering to a subject in need of such treatment a fusion polypeptide comprising an amino acid sequence selected from the group consisting of:

• APARSPSPSTQPWEHVNAIQEARRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLE LYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDC WEPVQEGAEAAAKEAAAKAGARRGVRVAWREPGRMELNMPHGQE (SEQ ID NO:
• 17);
• APARSPSPSTQPWEHVNAIQEARRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLE LYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDC WEPVQEGSAGSAAGSGARRGVRVAWREPGRMELNMPHGQE (SEQ ID NO:
• 18);
• METDTLLLWVLLLWVPGSTGREEFEEEFEHREEFEFEENLYFQGAPARSPSPSTQPWEHVNAIQE ARRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMM ASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQEGAEAAAKEAAAKA GARRGVRVAWREPGRMELNMPHGQE (SEQ ID NO:
• 19);
• 1VIETDTLLLWVLLLWVPGSTGREEFEEEFEHREEFEFEENLYFQGAPARSPSPSTQPWEHVNAIQE ARRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMM ASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQEGSAGSAAGSGARR GVRVAWREPGRMELNMPHGQE (SEQ ID NO:
• 40);
• METDTLLLWVLLLWVPGSTGREEFEEEFEHREEFEHENLYFQGARRGVHVGWREPGRMELN MPHGGAEAAAKEAAAKAGAPARSPSPSTQPWEHVNAIQEARRLLNLSRDTAAEMNET VEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCAT QIITFESFKENLKDFLLVIPFDCWEPVQE (SEQ ID NO:
• 36);
• and
• RRGVHVGWREPGRMELNMPHGGAEAAAKEAAAKAGAPARSPSPSTQPWEHVNAIQEA RRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMA SHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE (SEQ ID NO:
• 39) in an amount sufficient to treat the infection.

A method of treating cancer in a subject comprising administering to a subject in need of such treatment a fusion polypeptide comprising an amino acid sequence selected from the group consisting of:

• APARSPSPSTQPWEHVNAIQEARRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLE LYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDC WEPVQEGAEAAAKEAAAKAGARRGVRVAWREPGRMELNMPHGQE (SEQ ID NO:
• 17);
• APARSPSPSTQPWEHVNAIQEARRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLE LYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDC WEPVQEGSAGSAAGSGARRGVRVAWREPGRMELNMPHGQE (SEQ ID NO:
• 18);
• METDTLLLWVLLLWVPGSTGEEFEHTEHTIEEHTEHENLYFQGAPARSPSPSTQPWEHVNAIQE ARRLLNLSRDTAAEMNETVEVISEWDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMM ASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQEGAEAAAKEAAAKA GARRGVRVAWREPGRMELNMPHGQE (SEQ ID NO:
• 19);
• METDTLLLWVLLLWVPGSTGEEFEHTEHTIRFEFEHENLYFQGAPARSPSPSTQPWEHVNAIQE ARRLLNLSRDTAAEMNETVEVISEWDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMM ASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQEGSAGSAAGSGARR GVRVAWREPGRMELNMPHGQE (SEQ ID NO:
• 40);
• METDTLLLWVLLLWVPGSTGEEFEHTEHTIRFEFEHENLYFQGARRGVHVGWREPGRMELN MPHGGAEAAAKEAAAKAGAPARSPSPSTQPWEHVNAIQEARRLLNLSRDTAAEMNET VEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCAT QIITFESFKENLKDFLLVIPFDCWEPVQE (SEQ ID NO:
• 36);
• and
• RRGVHVGWREPGRMELNMPHGGAEAAAKEAAAKAGAPARSPSPSTQPWEHVNAIQEA RRLLNLSRDTAAEMNETVEVISEWDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMA SHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE (SEQ ID NO:
• 39) in an amount sufficient to treat the cancer.